User:Charles Swofford/Sandbox 1
From Proteopedia
| Line 3: | Line 3: | ||
<scene name='User:Charles_Swofford/Sandbox_1/1/22'>TRAIL</scene> | <scene name='User:Charles_Swofford/Sandbox_1/1/22'>TRAIL</scene> | ||
| + | |||
| + | TRAIL, or tumor-necrosis factor apoptosis-inducing ligand, is a member of the TNF superfamily that has attracted attention for its specificity towards cancer cells with limited toxicity towards most normal cells. TRAIL is a type II transmembrane protein with an extracellular domain that can be proteolyticly cleaved, and which forms a homotrimer that binds three monomeric death receptors (DRs). It binds to DR4 and DR5, which elicit signal transduction of caspase-8 mediated apoptosis via the death receptor pathway, or it can bind to the decoy receptors (DcR1, DcR2, or osteoprotegerin) which have truncated or non-functional intracellular death domains. Receptor binding by TNFα can stimulate both pro-apoptotic signals (via caspase-8) and anti-apoptotic signals (via NFκB). However, TRAIL has attenuated induction of NFκB, leading to a pronounced death signal via a p53-independent mechanism. In addition, the antagonistic decoy receptors are widely-expressed in normal tissues and confer a resistance to TRAIL-mediated apoptosis. | ||
Revision as of 19:28, 28 April 2010
|
TRAIL, or tumor-necrosis factor apoptosis-inducing ligand, is a member of the TNF superfamily that has attracted attention for its specificity towards cancer cells with limited toxicity towards most normal cells. TRAIL is a type II transmembrane protein with an extracellular domain that can be proteolyticly cleaved, and which forms a homotrimer that binds three monomeric death receptors (DRs). It binds to DR4 and DR5, which elicit signal transduction of caspase-8 mediated apoptosis via the death receptor pathway, or it can bind to the decoy receptors (DcR1, DcR2, or osteoprotegerin) which have truncated or non-functional intracellular death domains. Receptor binding by TNFα can stimulate both pro-apoptotic signals (via caspase-8) and anti-apoptotic signals (via NFκB). However, TRAIL has attenuated induction of NFκB, leading to a pronounced death signal via a p53-independent mechanism. In addition, the antagonistic decoy receptors are widely-expressed in normal tissues and confer a resistance to TRAIL-mediated apoptosis.
